Sophion Bioscience is a biotechnology company founded in 2000 with a focus on pioneering ion channels. The company's mission is to make patch clamping more objective and independent of user skills, providing faster, more accurate, and objective results. Over the past two decades, Sophion has evolved into a global organization while maintaining its passion and commitment to high-performance patch clamp solutions.
The company offers complete technical, biological, and application support to help partners achieve their targets. Through the development of the QPatch and Qube platforms, Sophion ensures uncompromised data quality in a user-friendly environment from assay setup to data analysis.
Sophion operates within the Biotechnology, Health Care, and Life Sciences industries, positioning itself at the intersection of cutting-edge technology and medical advancements. Despite the absence of specific headquarter information and recent investment details, Sophion's dedication to innovating patch clamping technology and providing comprehensive support makes it an intriguing prospect for potential investors seeking opportunities in the biotechnology sector.
There is no investment information
No recent news or press coverage available for Sophion Bioscience.